Benitec continues FDA discussions on BB-301 for OPMD, with additional data requested and pivotal study design confirmation targeted for Q1 2027.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Benitec Biopharma has announced formal feedback from the U.S. Food and Drug Administration (FDA) following a Type C meeting held in the third quarter of 2026 regarding the development of BB-301 for oculopharyngeal muscular dystrophy (OPMD).
Discussions with the FDA regarding the design of an open-label, single-arm pivotal study remain ongoing. As part of the regulatory discussions, the FDA has requested additional available data, including information from Benitec’s OPMD Natural History Study. The agency has agreed to review the requested information on a timeline that would allow Benitec to confirm the final pivotal study design in the first quarter of 2027.
Benitec currently plans to begin patient enrollment in the pivotal study in mid-2027.
BB-301 Uses a Silence-and-Replace Approach
OPMD is a rare autosomal-dominant muscle disorder caused by mutations in the PABPN1 gene, which encodes poly(A)-binding protein nuclear 1 (PABPN1), a protein involved in regulating mRNA poly(A) tail length.
Progressive dysphagia, or difficulty swallowing, is a major clinical manifestation of OPMD and can substantially affect nutrition and quality of life. Benitec estimates that OPMD affects nearly 15,000 people across North America, Europe and Israel. There are currently no approved therapies for the disease.
BB-301 is a modified adeno-associated virus serotype 9 (AAV9) capsid carrying a bifunctional genetic construct designed to simultaneously suppress mutant PABPN1 and provide functional PABPN1 protein.
The construct promotes expression of codon-optimized PABPN1 together with two small inhibitory RNAs (siRNAs) targeting mutant PABPN1. The siRNAs are incorporated into microRNA backbones to facilitate their processing within cells.
This “silence-and-replace” strategy is designed to reduce production of the faulty mutant PABPN1 while providing a functional replacement protein. BB-301 is administered locally in a one-time intramuscular procedure targeting the throat muscles involved in swallowing, with the aim of providing a localized therapeutic effect while limiting systemic exposure.
Clinical Development of BB-301
BB-301 is being evaluated in a Phase 1b/2a, first-in-human, open-label dose-escalation study in patients with OPMD (NCT06185673). The study is evaluating the safety and clinical activity of intramuscular BB-301.
The investigational therapy has received Orphan Drug Designation from the European Medicines Agency and both Orphan Drug and Fast Track Designations from the FDA.
Benitec plans to present interim clinical findings from the ongoing Phase 1b/2a study as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, from October 27 to 30, 2026.
The presentation is expected to include 12-month follow-up data for all six patients in Cohort 1 and interim follow-up data for all three patients in Cohort 2.
Next Steps for the Pivotal Program
The latest FDA feedback represents an additional step toward defining the pivotal development pathway for BB-301. However, the pivotal study design has not yet been finalized, and regulatory discussions remain ongoing.
Benitec said the additional data requested by the FDA represent an important component of the remaining development work. The company remains focused on using its clinical and natural history data to support confirmation of the pivotal study design in the first quarter of 2027 and planned patient enrollment in mid-2027.
If development proceeds as planned, BB-301 could potentially become the first approved disease-modifying therapy for patients with OPMD-related dysphagia. The upcoming clinical data and ongoing FDA discussions will provide further information on the development path for this investigational gene therapy.
Reference
“Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study, Benitec Biopharma, 05 October 2026
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects with Oculopharyngeal Muscular Dystrophy with Dysphagia, ClinicalTrials.gov ID NCT06185673
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.